Machine Learning-Based Analysis of ECG and PCG Signals for Rheumatic Heart Disease Detection: A Scoping Review (2015-2025)

TL;DR

This review highlights the potential of machine learning applied to ECG and PCG signals for scalable, accessible rheumatic heart disease screening, emphasizing recent advances, current challenges, and future needs for clinical implementation.

Contribution

It systematically reviews ML applications from 2015-2025 for RHD detection, identifying gaps in validation, data diversity, and real-world applicability, and provides practical recommendations.

Findings

CNNs achieve median accuracy of 97.75%

Most studies use private, single-center datasets

Few studies validate models externally or assess cost-effectiveness

Abstract

AI-powered stethoscopes offer a promising alternative for screening rheumatic heart disease (RHD), particularly in regions with limited diagnostic infrastructure. Early detection is vital, yet echocardiography, the gold standard tool, remains largely inaccessible in low-resource settings due to cost and workforce constraints. This review systematically examines machine learning (ML) applications from 2015 to 2025 that analyze electrocardiogram (ECG) and phonocardiogram (PCG) data to support accessible, scalable screening of all RHD variants in relation to the World Heart Federation's "25 by 25" goal to reduce RHD mortality. Using PRISMA-ScR guidelines, 37 peer-reviewed studies were selected from PubMed, IEEE Xplore, Scopus, and Embase. Convolutional neural networks (CNNs) dominate recent efforts, achieving a median accuracy of 97.75%, F1-score of 0.95, and AUROC of 0.89. However, challenges remain: 73% of studies used single-center datasets, 81.1% relied on private data, only 10.8% were externally validated, and none assessed cost-effectiveness. Although 45.9% originated from endemic regions, few addressed demographic diversity or implementation feasibility. These gaps underscore the disconnect between model performance and clinical readiness. Bridging this divide requires standardized benchmark datasets, prospective trials in endemic areas, and broader validation. If these issues are addressed, AI-augmented auscultation could transform cardiovascular diagnostics in underserved populations, thereby aiding early detection. This review also offers practical recommendations for building accessible ML-based RHD screening tools, aiming to close the diagnostic gap in low-resource settings where conventional auscultation may miss up to 90% of cases and echocardiography remains out of reach.